Vertex Bioenergy has secured long-term financing of approximately €350 million. The new platform financing streamlines the ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

It will operate under the ownership of certain of Vertex’s lenders, including funds managed by BlackRock Financial Management, Highbridge Capital Management, Whitebox Advisors and CrowdOut Capital ...

Under the terms of the chapter 11 plan confirmed by the U.S. Bankruptcy Court for the Southern District of Texas (the “Plan”), Vertex exited bankruptcy with a commitment of up to $100 million ...

Refined fuels company Vertex Energy has a new CEO and a new board of directors upon exiting Chapter 11 bankruptcy protection. Vertex Energy Inc., which filed for Chapter 11 bankruptcy protection ...

Vertex Energy has emerged as a privately held company after emerging from Chapter 11 bankruptcy. The company company filed for protections in 2024 after spending on equipment to produce biofuels ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates, ...

Vertex Energy Inc (OTC:VTNRQ)., a petroleum refining company, disclosed its monthly operating reports for the periods ended September 30, October 31, and November 30 of 2024 as part of its ongoing ...

Vertex Energy Inc (OTC:VTNRQ)., a petroleum refining company, disclosed its monthly operating reports for the periods ended September 30, October 31, and November 30 of 2024 as part of its ongoing ...

Bioenergy Europe has released its 2024 Landscape Report, providing a detailed analysis of bioenergy’s role in supporting Europe’s transition to a net zero economy by 2050. The report delivers key ...

What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program that the HHS claims violates anti-kickback statutes. In a court filing on ...